Oracle Alpha’s Cytokinetics CYTK Stock Holding History

Oracle Alpha’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,206	Closed	-$518K	–	204
2023 Q4	$518K	Buy	+6,206	New	+$225K	0.67%	25

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Oracle Alpha's CYTK Position: Q1 2024 in Review

Oracle Alpha sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 6,206 shares — an estimated $518K sold.

Oracle Alpha first reported a position in CYTK in Q4 2023 and held it in 1 quarter. The position peaked at $518K in Q4 2023. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

Oracle Alpha reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
Oracle Alpha sold 6,206 Cytokinetics shares in Q1 2024, an estimated $518K.
Oracle Alpha first reported a position in Cytokinetics in Q4 2023 and held it in 1 quarter.
Oracle Alpha's Cytokinetics position peaked at $518K in Q4 2023.
390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.